Chronic Heart Failure

  • In 2014 the Journal of the American College of Cardiology published a 2 year 420-patient placebo-controlled trial which found that, for patients with chronic heart failure, 100 mg CoQ10 taken 3 times daily in addition to standard therapy reduced symptoms and major adverse cardiovascular events. [Source]
  • In 2013 the American Journal of Clinical Nutrition published a meta-analysis of select studies which found that CoQ10 may improve ejection fraction – an important measurement used to determine the amount of blood being pumped out of the heart – and reduce risk of heart attack in patients with congestive heart failure. [Source]
  • In 2005 Biofactors published a double-blind, placebo-controlled trial involving 21 patients which found that 4 weeks of CoQ10 supplementation improved the heart’s efficiency in circulating blood throughout the body in patients with chronic heart failure. [Source]
  • In 2014 ARYA Atherosclerosis published a 16-week, double-blind, placebo-controlled clinical trial involving 62 patients which found that the cholesterol-lowering drug atorvastatin (brand name Lipitor) combined with 100 mg CoQ10 twice daily was significantly more effective in improving important heart-health measurements compared to atorvastatin combined with a placebo. [Source]


  • In 2014 Arteriosclerosis, Thrombosis and Vascular Biology published an animal study which found that CoQ10 consumption blocked the progression of atherosclerosis in mice. The authors of the study determined that CoQ10 is a promising substance for the prevention and treatment of atherosclerosis in humans. [Source]


  • In 2002 Cephalalgia published a study which tested the effects of 150 mg/day of CoQ10 on 32 patients with a history of migraine headaches. The result was a 55 percent decrease in migraine frequency after a 3-month supplementation period. [Source]
  • In 2005 Neurology published a double-blind study involving 42 patients which found that CoQ10 was more effective than a placebo in controlling migraine headaches and was well tolerated. [Source]

Macular Degeneration

  • In 2001 Ophthalmologica published a study which found that 19 patients with age-related macular degeneration generally had lower CoQ10 levels than 19 aged-matched controls. Based on this data the authors theorize that CoQ10 may have a protective effect against macular degeneration. [Source]
  • In 2005 Opthalmologica published a double-blind, placebo-controlled trial involving 106 patients which found that CoQ10, along with acetyl-L-carnitine and omega-3 fatty acids were effective in treating early-stage macular degeneration. [Source]
  • In 2003 Opthalmologica published a study involving 28 patients which found that CoQ10 combined with acetyl-L-carnitine, polyunsaturated fatty acids and vitamin E was effective in improving retinal function in early stage age-related macular degeneration. [Source]
  • In 2009 Investigative Opthalmology & Visual Science published an in vitro study which found that CoQ10 levels in eye tissue can decline by 40 percent with age, which may be linked to the progression of macular degeneration. [Source]

Prevents Fatigue Caused by Multiple Sclerosis

  • In 2016 Nutritional Neuroscience published a double-blind clinical trial which found that 500 mg per day of CoQ10 was able to improve both fatigue and depression symptoms in patients with multiple sclerosis. [Source]

Stress-Related Depression

  • In 2013 Pharmacology Biochemistry and Behavior published an animal study which tested the effects of CoQ10 on rats with induced stress. The authors found CoQ10 to possess anti-depressive activity while protecting regions of the brain from stress-induced DNA damage. [Source]


  • In 2009 Neuro Endocrinology Letters published a study which examined the CoQ10 levels in 35 depressed and 22 normal individuals. The researchers found that more than half of the depressed patients had CoQ10 levels that were lower than the lowest values detected in individuals who were not depressed. [Source]


  • In 2015 Aging Cell published a study that showed CoQ10 production was lower in the ovarian cells of aging females. The authors theorize that CoQ10 supplementation could improve ovarian cell quality and quantity, potentially improving fertility of older females. [Source]

Alzheimer’s Disease

  • In 2011 the Journal of Alzheimer’s Disease published an animal study that demonstrated improvements in symptoms and behavior in mice with Alzheimer’s Disease after treatment with CoQ10. [Source]

Eye Protection

  • In 2014 Apoptosis published an animal study in which the authors determined that CoQ10 promotes the survival of retina cells in mice by reducing free radical activity. [Source]
  • In 2012 the Journal of Radiation Research published a study which found that CoQ10 was able to protect retina cells from ultraviolet radiation damage in both an animal model as well as in a test tube model. [Source]


  • In 2014 the Iranian Red Cresent Medical Journal published a double-blind, placebo-controlled clinical trial involving 52 patients with hyperlipidemia and myocardial infarction. Results showed 12 weeks of supplementation with 200 mg/day of CoQ10 reduced blood pressure and lowered cholesterol significantly more than a placebo. [Source]
  • In 2002 the European Journal of Clinical Nutrition published a double-blind study in which 74 type 2 diabetic patients with elevated cholesterol were assigned to either 200 mg per day CoQ10, fenofibrate (cholesterol-lowering drug), both or neither for 12 weeks. Results showed CoQ10 reduced both blood pressure and long-term glycaemic control while fenofibrate did not alter blood pressure at all. [Source]
  • In 2001 Southern Medical Journal published a 12-week, double-blind, placebo-controlled clinical trial involving 83 subjects which showed that 60 mg of CoQ10 taken twice daily lead to a significant drop in average systolic blood pressure. [Source]
  • In 2015 the Journal of Sports Medicine and Physical Fitness published a 32-subject, double-blind, placebo-controlled trial which found that 600 mg daily of CoQ10 supplemented for 11 days (starting 7 days prior to camp) resulted in a significant reduction in blood pressure in young athletes during a 4-day training camp. [Source]
  • In 2007 the Journal of Human Hypertension published a meta-analysis of 12 clinical trials which showed that, in hypertensive individuals, CoQ10 has the potential to reduce systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects. [Source]


  • In 2013 Redox Report published a study which linked juvenile fibromyalgia to deficient levels of coenzyme Q10. Results showed that 100 mg/day CoQ10 for 12 weeks in fibromyalgia patients lead to reductions in cholesterol and reduced symptoms of chronic fatigue. [Source]
  • In 2013 Nutrition published a study that showed that 4 fibromyalgia sufferers were deficient in CoQ10. According to the authors, after supplementation with CoQ10, all patients showed improvements in symptoms. [Source]
  • In 2015 Antioxidants & Redox Signaling published a double-blind study in which 73 patients with chronic fatigue syndrome – a disorder common in fibromyaglia patients – were treated with either 200 mg/day CoQ10 and 20 mg/day NADH or a placebo for 8 weeks. Results showed that CoQ10/NADH significantly reduced fatigue and improved biochemical parameters of CFS with no adverse effects. [Source]
Scroll to Top
Scroll to Top